Latest Clobetasol Propionate Stories

Stiefel Laboratories, Inc., the world's largest independent pharmaceutical company specializing in dermatology, today announced that the U.S. Food and Drug Administration (FDA) has approved Olux-E™ (clobetasol propionate) Foam, 0.05%. Olux-E is indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, also known as psoriasis and eczema, in patients 12 years of age or older. In clinical studies, Olux-E was shown to safely and...